Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Solid Carcinoma”

2,028 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 2,028 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05608876
What this trial is testing

A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer

Who this might be right for
Head and Neck Cancer
QBiotics Group Limited 15
Early research (Phase 1)Looking for participantsNCT05176483
What this trial is testing

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Who this might be right for
Renal Cell Carcinoma (RCC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)Urothelial Carcinoma (UC)+7 more
Exelixis 1,314
Testing effectiveness (Phase 2)Study completedNCT03665285
What this trial is testing

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced or Metastatic Solid TumorsLung CancerBreast Cancer+6 more
NextCure, Inc. 109
Early research (Phase 1)Study completedNCT01017185
What this trial is testing

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Who this might be right for
Refractory Head and Neck CancerSquamous Cell Carcinoma, SkinCarcinoma of the Breast+1 more
Takara Bio Inc. 28
Not applicableNot Yet RecruitingNCT07645742
What this trial is testing

Pilot Study of Intermittent Fasting With Immune Checkpoint Inhibitors

Who this might be right for
Cancer (Advanced Stage)
West Virginia University 90
Testing effectiveness (Phase 2)Active Not RecruitingNCT05585320
What this trial is testing

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid TumorPancreatic AdenocarcinomaMalignant Melanoma (Cutaneous)+1 more
Immuneering Corporation 209
Testing effectiveness (Phase 2)Ended earlyNCT06024174
What this trial is testing

BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

Who this might be right for
Advanced Solid Tumors
Bristol-Myers Squibb 5
Testing effectiveness (Phase 2)Active Not RecruitingNCT04699188
What this trial is testing

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Who this might be right for
KRAS G12C Mutant Solid TumorsCarcinoma, Non-Small-Cell LungCarcinoma, Colorectal+7 more
Novartis Pharmaceuticals 344
Testing effectiveness (Phase 2)Ended earlyNCT01065805
What this trial is testing

Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma

Who this might be right for
Brain CancerCancerSolid Tumor+1 more
AHS Cancer Control Alberta 94
Early research (Phase 1)Study completedNCT02955251
What this trial is testing

ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors Cancer
AbbVie 61
Early research (Phase 1)Study completedNCT02451553
What this trial is testing

Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer

Who this might be right for
Advanced Malignant Solid NeoplasmBile Duct CarcinomaRecurrent Malignant Solid Neoplasm+4 more
University of Washington 41
Testing effectiveness (Phase 2)Looking for participantsNCT06923761
What this trial is testing

EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)

Who this might be right for
Advanced Solid Malignancy
Grey Wolf Therapeutics 300
Testing effectiveness (Phase 2)Looking for participantsNCT06616766
What this trial is testing

A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)Solid Tumor
Yuhan Corporation 161
Early research (Phase 1)Study completedNCT03739931
What this trial is testing

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Who this might be right for
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or LymphomaDose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
ModernaTX, Inc. 134
Early research (Phase 1)Ended earlyNCT04099277
What this trial is testing

LY3435151 in Participants With Solid Tumors

Who this might be right for
Solid TumorTriple-negative Breast CancerGastric Adenocarcinoma+6 more
Eli Lilly and Company 2
Testing effectiveness (Phase 2)Looking for participantsNCT07410494
What this trial is testing

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Who this might be right for
CancerBreast CancerNon-Small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech 85
Early research (Phase 1)Study completedNCT03518554
What this trial is testing

A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors

Who this might be right for
Non-small Cell Lung CancerHead and Neck CancerEsophageal Cancer+1 more
Jacobio Pharmaceuticals Co., Ltd. 38
Early research (Phase 1)Ended earlyNCT04800822
What this trial is testing

PF-07284892 in Participants With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Pfizer 53
Not applicableApproved For MarketingNCT04100694
What this trial is testing

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Who this might be right for
NRG1 FusionPancreatic CancerNon Small Cell Lung Cancer+8 more
Merus B.V.
Early research (Phase 1)Not Yet RecruitingNCT06748872
What this trial is testing

EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma

Who this might be right for
Epithelial Ovarian CancerGastro-esophageal Junction CancerSoft Tissue Sarcoma (STS)+2 more
Medigene AG 55
Load More Results